These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27443592)

  • 1. Decrease in circulating CD25(hi)Foxp3(+) regulatory T cells following vaccination with the candidate malaria vaccine RTS,S.
    Parsons E; Epstein J; Sedegah M; Villasante E; Stewart A
    Vaccine; 2016 Aug; 34(38):4618-4625. PubMed ID: 27443592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.
    Lalvani A; Moris P; Voss G; Pathan AA; Kester KE; Brookes R; Lee E; Koutsoukos M; Plebanski M; Delchambre M; Flanagan KL; Carton C; Slaoui M; Van Hoecke C; Ballou WR; Hill AV; Cohen J
    J Infect Dis; 1999 Nov; 180(5):1656-64. PubMed ID: 10515829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.
    Epstein JE; Charoenvit Y; Kester KE; Wang R; Newcomer R; Fitzpatrick S; Richie TL; Tornieporth N; Heppner DG; Ockenhouse C; Majam V; Holland C; Abot E; Ganeshan H; Berzins M; Jones T; Freydberg CN; Ng J; Norman J; Carucci DJ; Cohen J; Hoffman SL
    Vaccine; 2004 Apr; 22(13-14):1592-603. PubMed ID: 15068840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia.
    Pinder M; Reece WH; Plebanski M; Akinwunmi P; Flanagan KL; Lee EA; Doherty T; Milligan P; Jaye A; Tornieporth N; Ballou R; McAdam KP; Cohen J; Hill AV
    Clin Exp Immunol; 2004 Feb; 135(2):286-93. PubMed ID: 14738458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein.
    Wang R; Epstein J; Charoenvit Y; Baraceros FM; Rahardjo N; Gay T; Banania JG; Chattopadhyay R; de la Vega P; Richie TL; Tornieporth N; Doolan DL; Kester KE; Heppner DG; Norman J; Carucci DJ; Cohen JD; Hoffman SL
    J Immunol; 2004 May; 172(9):5561-9. PubMed ID: 15100299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap.
    Kaslow DC; Biernaux S
    Vaccine; 2015 Dec; 33(52):7425-32. PubMed ID: 26431982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique.
    Barbosa A; Naniche D; Aponte JJ; Manaca MN; Mandomando I; Aide P; Sacarlal J; Renom M; Lafuente S; Ballou WR; Alonso PL
    Infect Immun; 2009 Oct; 77(10):4502-9. PubMed ID: 19651872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.
    Walsh DS; Gettayacamin M; Leitner WW; Lyon JA; Stewart VA; Marit G; Pichyangkul S; Gosi P; Tongtawe P; Kester KE; Holland CA; Kolodny N; Cohen J; Voss G; Ballou WR; Heppner DG
    Vaccine; 2006 May; 24(19):4167-78. PubMed ID: 16574282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
    Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
    Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.
    Sun P; Schwenk R; White K; Stoute JA; Cohen J; Ballou WR; Voss G; Kester KE; Heppner DG; Krzych U
    J Immunol; 2003 Dec; 171(12):6961-7. PubMed ID: 14662904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.
    Abdulla S; Oberholzer R; Juma O; Kubhoja S; Machera F; Membi C; Omari S; Urassa A; Mshinda H; Jumanne A; Salim N; Shomari M; Aebi T; Schellenberg DM; Carter T; Villafana T; Demoitié MA; Dubois MC; Leach A; Lievens M; Vekemans J; Cohen J; Ballou WR; Tanner M
    N Engl J Med; 2008 Dec; 359(24):2533-44. PubMed ID: 19064623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
    Stoute JA; Slaoui M; Heppner DG; Momin P; Kester KE; Desmons P; Wellde BT; Garçon N; Krzych U; Marchand M
    N Engl J Med; 1997 Jan; 336(2):86-91. PubMed ID: 8988885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.
    Bojang KA; Milligan PJ; Pinder M; Vigneron L; Alloueche A; Kester KE; Ballou WR; Conway DJ; Reece WH; Gothard P; Yamuah L; Delchambre M; Voss G; Greenwood BM; Hill A; McAdam KP; Tornieporth N; Cohen JD; Doherty T;
    Lancet; 2001 Dec; 358(9297):1927-34. PubMed ID: 11747915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
    Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
    Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy.
    Chinchilla M; Pasetti MF; Medina-Moreno S; Wang JY; Gomez-Duarte OG; Stout R; Levine MM; Galen JE
    Infect Immun; 2007 Aug; 75(8):3769-79. PubMed ID: 17502396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model.
    Dunachie S; Berthoud T; Hill AV; Fletcher HA
    Vaccine; 2015 Sep; 33(40):5321-31. PubMed ID: 26256523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP.
    Rampling T; Ewer KJ; Bowyer G; Bliss CM; Edwards NJ; Wright D; Payne RO; Venkatraman N; de Barra E; Snudden CM; Poulton ID; de Graaf H; Sukhtankar P; Roberts R; Ivinson K; Weltzin R; Rajkumar BY; Wille-Reece U; Lee CK; Ockenhouse CF; Sinden RE; Gerry S; Lawrie AM; Vekemans J; Morelle D; Lievens M; Ballou RW; Cooke GS; Faust SN; Gilbert S; Hill AV
    J Infect Dis; 2016 Sep; 214(5):772-81. PubMed ID: 27307573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.
    Stoute JA; Kester KE; Krzych U; Wellde BT; Hall T; White K; Glenn G; Ockenhouse CF; Garcon N; Schwenk R; Lanar DE; Sun P; Momin P; Wirtz RA; Golenda C; Slaoui M; Wortmann G; Holland C; Dowler M; Cohen J; Ballou WR
    J Infect Dis; 1998 Oct; 178(4):1139-44. PubMed ID: 9806046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MIG and the regulatory cytokines IL-10 and TGF-β1 correlate with malaria vaccine immunogenicity and efficacy.
    Dunachie SJ; Berthoud T; Keating SM; Hill AV; Fletcher HA
    PLoS One; 2010 Sep; 5(9):e12557. PubMed ID: 20838432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.
    Heppner DG; Kester KE; Ockenhouse CF; Tornieporth N; Ofori O; Lyon JA; Stewart VA; Dubois P; Lanar DE; Krzych U; Moris P; Angov E; Cummings JF; Leach A; Hall BT; Dutta S; Schwenk R; Hillier C; Barbosa A; Ware LA; Nair L; Darko CA; Withers MR; Ogutu B; Polhemus ME; Fukuda M; Pichyangkul S; Gettyacamin M; Diggs C; Soisson L; Milman J; Dubois MC; Garçon N; Tucker K; Wittes J; Plowe CV; Thera MA; Duombo OK; Pau MG; Goudsmit J; Ballou WR; Cohen J
    Vaccine; 2005 Mar; 23(17-18):2243-50. PubMed ID: 15755604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.